Overactive urinary bladder
Drug research and approvals for overactive urinary bladder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 77 studies of overactive urinary bladder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 77
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 77 recruiting on ClinicalTrials.gov ↗- Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson DiseaseNCT07187466 · Phase 4 · VA Office of Research and Development · starts Nov 9, 2026
- Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive BladderNCT07773532 · Not reported · Bagcilar Training and Research Hospital · starts Nov 2, 2026
- Peroneal Transcutaneous Neuromodulation in Children With Overactive BladderNCT07939061 · Not applicable · General University Hospital, Prague · starts Sep 3, 2026
- Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone…NCT07662824 · Not applicable · Mayo Clinic · starts Aug 20, 2026
- Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive BladderNCT07540273 · Not applicable · SEZGIN · starts Aug 15, 2026
- Electroacupuncture as a Treatment for Refractory Overactive BladderNCT07124390 · Not applicable · Chelsea and Westminster NHS Foundation Trust · starts Aug 15, 2026
- RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of…NCT07553065 · Phase 2 · Vensica Therapeutics Ltd. · starts Aug 14, 2026
- Does Use of a Pre-Procedure Educational Video for Urodynamic Testing Reduces Anxiety?NCT07740629 · Not applicable · Yair Daykan · starts Aug 1, 2026
- Self-Start Triage Model for Post-Botox® Lower Urinary Tract SymptomsNCT07648290 · Early Phase 1 · The Cleveland Clinic · starts Jul 31, 2026
- Fluoroscopy Radiation Reduction During Sacral Neuromodulation Lead PlacementNCT04527445 · Not applicable · Loma Linda University · starts Jun 1, 2026
Drug Pipeline
9 approved, 7 in phase 3, 16 in phase 2, 7 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Mirabegron, Tolterodine, Solifenacin, Fesoterodine, Oxybutynin, Vibegron, Darifenacin, Trospium, Botulinum toxin type a
- Onabotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Ritobegron
- Phase 3 Beta-3 adrenergic receptor agonist
- Imidafenacin
- Phase 3 Muscarinic acetylcholine receptor M3 antagonist
- Incobotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Lidocaine
- Phase 3 Sodium channel alpha subunit blocker
- Dimethyl sulfoxide
- Phase 3 Unknown
- Propiverine
- Phase 3
- Solabegron
- Phase 2 Beta-3 adrenergic receptor agonist
- Burapitant
- Phase 2 Neurokinin 1 receptor antagonist
- Tarafenacin
- Phase 2 Muscarinic acetylcholine receptor M3 antagonist
- Casopitant
- Phase 2 Neurokinin 1 receptor antagonist
- Eliapixant
- Phase 2
- Desmopressin
- Phase 2 Vasopressin receptor agonist
- Estrogens, conjugated
- Phase 2 Estrogen receptor agonist
- Vardenafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Pregabalin
- Phase 2 Voltage-gated calcium channel modulator
- Afacifenacin
- Phase 2 Muscarinic acetylcholine receptor antagonist
- Dexmecamylamine
- Phase 2 Neuronal acetylcholine receptor; alpha4/beta2 antagonist
- ONO-8539
- Phase 2 Prostanoid EP1 receptor antagonist
- Gisadenafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Lactose, anhydrous
- Phase 2
- Senrebotase
- Phase 2
- Warfarin
- Phase 1 Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Propantheline
- Phase 1 Muscarinic acetylcholine receptor M3 antagonist
- Fluconazole
- Phase 1 Cytochrome P450 51 inhibitor
- Cephalexin anhydrous
- Phase 1 Bacterial penicillin-binding protein inhibitor
- Levofloxacin anhydrous
- Phase 1 DNA gyrase inhibitor
- Sunobinop
- Phase 1
- Velufenacin
- Phase 1
How Its Trials Ended
794 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 188 whose ending is known, 51% met their primary endpoint, 2% missed it and 47% stopped early.
- Completed, result not reported38649%
- Status unknown11314%
- Ongoing10713%
- Met its primary endpoint9612%
- Stopped: other or unclear405%
- Stopped: enrollment or feasibility304%
- Stopped: lack of efficacy61%
- Stopped: sponsor or business decision51%
- Missed its primary endpoint41%
- Stopped: safety41%
- Stopped: funding30%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA